Navigation Links
Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
Date:6/15/2010

re being used primarily in connection with perifosine, Aeterna Zentaris' lead oncology compound that is being developed in collaboration with its North American partner, Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), following various positive developments announced with respect to perifosine during the first quarter of 2010.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. A shelf registration statement relating to the common shares and warrants issued in the offering (and the common shares issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective. A prospectus supplement relating to the offering will be filed by the Company with the SEC and the Canadian securities regulatory authorities. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company or by contacting Aeterna Zentaris Inc., 1405 du Parc-Technologique Boulevard, Quebec City, Canada G1P 4P5.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
2. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
3. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
4. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
5. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
7. AEterna Zentaris Announces Appointment of New Board Member
8. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
9. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
11. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... BETHESDA, Md. , May 6, 2015  Northwest Biotherapeutics ... personalized immune therapies for solid tumor cancers, today announced that ... overview of the Company,s DCVax cancer vaccine platform for solid ... on May 7, 2015.   , ... , , , , TIME: , , , 12:15 ...
(Date:5/6/2015)... Dr Jaspreet Singh , Senior Research ... a speech at the 2015 Asian Starch Conference, to be ... Center.  , ... topic: ,Potato Starch: A Potential Source for the Creation ... Co-editor of a 528 page text book entitled "Advances ...
(Date:5/5/2015)... WARREN, N.J. , May 5, 2015 Roka ... focused on providing advanced testing solutions for the detection of ... will present at the Bank of America Merrill Lynch 2015 ... conference will be held at Encore at the Wynn, ... live webcast of the presentation will be available through the ...
(Date:5/5/2015)... Mass. , May 5, 2015 Psyche ... strategic alliance which offers a first-of-its-kind platform that helps ... access to lab results, transforms the way patients engage ... Luminate Health provides a HIPAA-compliant digital ... to access, manage, and understand their lab results, and ...
Breaking Biology Technology:NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3
... available types of synthetic skin may now be good enough ... on their way to truly simulating human skin in the ... to rat skin when they were both exposed to a ... reacted similarly. The scientists used high-resolution images of two ...
... KellBenx, a biotechnology company focused on the development ... disorders, announced today that it has signed an exclusive ... new blood test that could predict the risk of ... women become pregnant. Preterm delivery (PTD) is the leading ...
... Maryland researchers have discovered a way to control magnetic properties ... magnetic storage and magnetic random access memory. The finding ... Michael S. Fuhrer of the UMD Center for Nanophysics and ... for graphene. A honeycomb sheet of carbon atoms just ...
Cached Biology Technology:For testing skin cream, synthetic skin may be as good as the real thing 2For testing skin cream, synthetic skin may be as good as the real thing 3KellBenx Secures Worldwide Agreement With Cedars-Sinai Medical Center for Biomarker Technology to Predict Premature Births 2UMD scientists make magnetic new graphene discovery 2
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... an iconic symbol of America on everything from coins to ... are exploring how the cross-breeding of bison with domestic cattle ... modern populations of the species. "The plains bison are ... survive," said Professor James Derr from Texas A&M University. "The ...
... top national award for promising research scientists has been ... of biology at Rutgers UniversityCamden. Yakoby has received ... The five-year, $686,544 award, which is reviewed and ... project, supports the RutgersCamden researcher,s project "Dynamics and Diversity ...
... 2012  GHX today announced successful results from its ... The company began rolling out the first phase ... sites including both healthcare provider and manufacturer organizations. ... use, GHX believes better management of clinical, operational ...
Cached Biology News:Study reveals impact of historical domestic cattle hybridization with American bison 2Rutgers-Camden genetics researcher receives NSF CAREER Award 2Pilot Results Move GHX Closer to Delivery of Healthcare Industry's First Implantable Device Supply Chain Solution 2Pilot Results Move GHX Closer to Delivery of Healthcare Industry's First Implantable Device Supply Chain Solution 3Pilot Results Move GHX Closer to Delivery of Healthcare Industry's First Implantable Device Supply Chain Solution 4
... Synthesis and Labeling Kit generates labeled cDNA ... unmodified cDNA is made via a reverse ... Oligo(dT) primer. Unlike other methods, there are ... reverse transcription reaction. This unmodified cDNA is ...
The Piezo Power MicroDissection (PPMD) system is designed for rapid isolation of single cells or small cell areas...
... specifically for Alkaline Phosphatase conjugates. The ... for both the enzyme and the antibody ... This product has been chemically engineered to ... longer shelf life, resistance to various shipping ...
AC input: 50-60 Hz230 V...
Biology Products: